Observation of Anti-vascular Endothelial Growth Factor Therapy in Exudative Age-related Macular Degeneration, Proliferative Diabetic Retinopathy, Macular Edema, and Choroidal Neovascularization.
| Registry | NCT05222633 |
|---|---|
| Status | Unknown |
| Study type | Observational |
| Enrollment | 1000 (Estimated) |
| Sponsor | Wenbin Wei (Other) |
| Conditions | Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane, Non-proliferative Diabetic Retinopathy, Retinal Vein Occlusion, Proliferative Diabetic Retinopathy |
| Interventions | Ranibizumab, Aflibercept, Conbercept (Drug) |
| Dates | start 2022-01-01, primary completion 2023-01-01 (estimated), completion 2023-05-01 (estimated), first posted 2022-02-03, last updated 2022-02-03 |
| Locations | 1 site in China |
Related Papers Related Patents Related Grants Related Experts
All trials for Neovascular Age-related Macular Edema All trials for Diabetic Macular Edema All trials of Ranibizumab All trials of Aflibercept
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-vascular endothelial growth factor therapy drugs. In the current study, the primary aim is to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases, including neovascular age-related macular edema, diabetic macula edema/non-proliferative diabetic retinopathy / proliferative diabetic retinopathy, retinal vein occlusions related macular edema, and choroidal neovascularization secondary to multiple retinal diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-VEGF drugs. In the current study, the primary aim is to aim to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Neovascular age-related macular edema | Drug: Ranibizumab; Drug: Aflibercept; Drug: Conbercept | Patients with new-onset and recurrent Neovascular age-related macular edema. | |
| Diabetic macula edema | Drug: Ranibizumab; Drug: Aflibercept; Drug: Conbercept | Patients with new-onset and recurrent diabetic macula edema | |
| Non-proliferative diabetic retinopathy/proliferative diabetic retinopathy | Drug: Ranibizumab; Drug: Aflibercept; Drug: Conbercept | Patients with new-onset and recurrent non-proliferative diabetic retinopathy/proliferative diabetic retinopathy | |
| Retinal vein occlusions | Drug: Ranibizumab | Patients with new-onset and recurrent retinal vein occlusions | |
| Choroidal neovascularization | Drug: Ranibizumab; Drug: Aflibercept; Drug: Conbercept | Patients with new-onset and recurrent choroidal neovascularization |
Sex: All, ages: 35 Years to 80 Years, accepts healthy volunteers
Inclusion Criteria: * Patients with neovascular age-related macular edema (nAMD), diabetic macula edema (DME)/non-proliferative diabetic retinopathy (NPDR)/ proliferative diabetic retinopathy (PDR), retinal vein occlusions related macular edema, and choroidal neovascular (CNV) secondary to multiple retinal diseases. * Undergo intravitreal anti-VEGF therapy Exclusion Criteria: * unable to receive OCT examination * Severe corneal opacity, cataract that affect OCT examination
| Facility | City | Country | Status |
|---|---|---|---|
| Wen-Bin Wei | Beijing, Beijing Municipality | China | Recruiting |